Table 1

Patient characteristics and details of COVID-19

ID	Age, sex	ANCA serotype	Concomitant immunosuppressant at the time of COVID-19	Vaccination status	Spike antibody level*	Prevailing COVID-19 variant	Days from induction treatment to COVID-19	COVID-19 treatment	COVID-19 severity	Outcome	Long COVID
1	83F	MPO	RTX	3 mRNA doses during BCD	Positive	Omicron	165	Nirmatrelvir/ritonavir	Mild	Resolved	No
2	54F	PR3	RTX	3 mRNA doses preceding BCD	NT	Omicron	77	Nirmatrelvir/ritonavir	Mild	Resolved	No
3	71M	PR3	RTX	2 mRNA doses preceding BCD, 1 mRNA dose after BCD	Positive	Omicron	160	Molnupiravir	Mild	Resolved	No
4	81M	PR3	RTX, CYC prednisone 15 mg	3 mRNA doses preceding BCD	NT	Omicron	55	Remdesivir, dexamethasone	Severe	Death	No
5	58F	MPO	RTX prednisone 5 mg	2 mRNA doses preceding BCD	NT	Omicron	123	None	Mild	Resolved	No
6	58F	MPO	RTX	3 mRNA doses preceding BCD	Positive	Omicron	108	Bebtelovimab	Mild	Resolved	No
7	75M	MPO	RTX	2 mRNA doses preceding BCD, 1 mRNA dose after BCD	Negative	Omicron	280	None	Mild	Resolved	No
8	34M	MPO	RTX	3 mRNA doses preceding BCD	NT	Omicron	67	Nirmatrelvir/ritonavir	Mild	Resolved	No

*Positive spike antibody levels preceding this episode of COVID-19 resulted from either vaccination or prior infection during peripheral B cell presence, or through prior receipt of tixagevimab/cilgavimab.
ANCA, antineutrophil cytoplasmic antibody; BCD, B cell depletion; CYC, cyclophosphamide; F, female; M, male; MPO, myeloperoxidase; mRNA, messenger RNA; NT, not tested; PR3, proteinase-3; RTX, rituximab.